Page 2484 - Williams Hematology ( PDFDrive )

2455
2454 Index Index 2455

for chronic lymphocytic leukemia, 1541 IRIS (immune reconstitution inflammatory etiology, 628
for immune-related myelofibrosis, 1330 syndrome), 1242 blood loss, 628–630, 628t
for immune thrombocytopenia, 2000, Iron dietary, 630
2003, 2004–2005, 2011 bioavailability, 618–619 genetic, 631
for neuropathy, 1724 dietary, 618–619, 618t hemoglobinuria, 631
for persistent B19 parvovirus infection, distribution, 617–618, 618t intravascular hemolysis, 631
544–545 inhibition of intestinal absorption of, 552 malabsorption, 630
for X-linked anhydrotic ectodermal labile pool, 618 paroxysmal nocturnal hemoglobinuria,
dysplasia, 1215 levels of, in newborn, 104 579
Intrinsic factor malabsorption, 630 in pregnancy, 120, 630
assays of, 603 metabolism iron metabolism in, 552, 553t
in cobalamin absorption, 591, 591t absorption and, 619–622, 619f laboratory features, 633–635, 633f, 634f,
congenital deficiency, 605 erythrocyte production and, 490–491, 638
in pernicious anemia, 18 491f, 491t pathogenesis, 631–633, 631f
Intrinsic mutagenesis theory of aging, 130, excretion and, 624–625 reactive thrombocytosis in, 2036
130t homeostasis and, 620–622, 620f, 621t, thrombocytopenia and, 1997
Introns, 147 623 treatment, 638–639
Invariant CD3 proteins, 1176, 1176f in iron deficiency anemia, 552, 553t Iron dextran, 639
Inversions, chromosomal macrophages in, 1063, 1065f Iron overload
in acute myelogenous leukemia, 180–181, regulation by hypoxia, 504f in congenital dyserythropoietic anemia,
1377, 1384t, 1414–1415 in sideroblastic anemia, 918 567
definition, 175t in thalassemia, 742 in myelodysplastic syndromes, 1358
Iodine, radioactive mitochondrial, 623–624 porphyria cutanea tarda and, 907
in plasma labeling, 488 in myoglobin, 618 in sickle cell disease, 776
in transplant preparation, 360 overload, 641. See also Hemochromatosis in sideroblastic anemia, 920
Ion Torrent platform, 157–158, 157f poisoning, 638–639 in thalassemias, 742
IP (inositol 1,4,5-triphosphate), 935, 1016, radioactive, in red cell labeling, 488 Iron protoporphyrin IX. See Heme
3
1836, 1840 recycling, 619 Iron-regulatory protein (IRP-1), 623, 624f
Ipaf (interleukin-1-β-converting storage compartments, 617–618, 618t Iron-responsive elements (IREs), 623, 624f
enzyme-protease activating factor), therapeutic. See Iron therapy Iron storage disease, 639. See also
1066f toxicity, 640–641 Hemochromatosis
IPEX syndrome (immune dysregulation, transport, 622–624, 622f Iron stores, marrow, 34–35
polyendocrinopathy, enteropathy, erythroblast and, 623–624 Iron therapy, 638
X-linked syndrome), 1181, 1215t, across intestinal mucosa, 619, 620f for anemia of chronic kidney disease, 554t,
1223 intracellular iron homeostasis and, 623, 555
IPH2101, 1192 625f for anemia of inflammation, 554, 554t
IPS (idiopathic pneumonia syndrome), 368 transferrin endocytosis in, 622–623, iron overload and, 641
iPSCs (induced pluripotent stem cells), 623f, 624f oral, 638–639
448–449 turnover, 490–491, 490f parenteral, 639
IPS-I (interferon-β promoter stimulator unavailability, 551–552, 551f for paroxysmal nocturnal hemoglobinuria,
1). See Mitochondrial antiviral Iron-binding capacity, 634 579
signaling protein (MAVS) Iron chelation therapy IRP-1 (iron-regulatory protein), 623, 624f
IPSID (immunoproliferative small intestinal for congenital dyserythropoietic anemia, Irradiation. See also Radiation therapy
disease), 1663, 1665, 1808, 1809 567 platelets, 2388
IRAK (interleukin receptor-associated for hemochromatosis, 644 total-body, 353, 359–360
kinase), 298, 1230 for iron overload in sickle cell disease, 776 Irreversibly sickled cells (ISCs), 475, 764
IRAK (interleukin receptor-associated monitoring, 752 Isavuconazole, 385
kinase)-4 deficiency, 1054, 1230 for myelodysplastic syndromes, 1358 Ischemia, protein C activation and, 1954
IREs (iron-responsive elements), 623, 624f for thalassemias, 751–752 Ischemia pneumonitis, 2269
IRF (interferon response factor), 297f, 298 Iron cycle, 622f Ischemia–reperfusion injury, in sickle cell
IRF4 (interferon regulatory factor 4), Iron deficiency, 628–639 disease, 765
1171–1172, 1710, 1710f clinical features, 632–633 Ischemic stroke. See Stroke
IRF4 (MUM1), 234t course and prognosis, 639 ISCs (irreversibly sickled cells), 475, 764
IRF8 (interferon-regulated factor 8), 235t, definition and history, 628 ISG15 (interferon stimulated gene 15),
1231 differential diagnosis, 635–638, 635f, 636t 1231
Irinotecan, 326–327 epidemiology, 628 Isochromosome, 175t

Kaushansky_index_p2393-2506.indd 2455 9/21/15 3:22 PM